Keywords: cor, boosted, early, halt, integrilin, plus, stenting

COR boosted on early halt of Integrilin plus stenting study

Article | 07 February 2000

Print This

Shares in COR Therapeutics rose a massive 58.4% on February 4 to closeat $41.50 following an announcement that a trial of its gpIIb/ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in